Latest Headlines

Latest Headlines

Startup gets $36.5M to conduct U.S. pivotal trial for novel endoscopic weight loss device

Obesity treatment devices have been in the regulatory spotlight in 2015 with two approvals for balloon-based devices and another for a neurostimulator. That makes for a total of 5 FDA-approved obesity devices--including the two banding devices that were already approved.

Diabetes duodenal resurfacing startup Fractyl bumps Series C up to $57M

Crossover investor Deerfield Management has joined the syndicate of Fractyl Laboratories with a $17 million addition to a Series C financing to bring it up to a total of $57 million. The startup will use the cash to continue backing clinical testing of its Revita Duodenal Mucosal Resurfacing System, which has already started an international multicenter trial and is slated to begin randomized studies in 2016.

With just 50 reps to Takeda's 900, Vivus' Qsymia beats Contrave on Q3 sales

Takeda has 900 reps behind Orexigen's Contrave--but is that investment worth it? Maybe not, RBC Capital Markets' Simos Simeonidis suggested recently in a note to investors. Vivus' Qsymia--with just 50 reps supporting the product--hauled in $14 million in Q3 revenue, compared with just $12.8 million for Contrave. 

Are Takeda's 900 Contrave reps worth it? Maybe not, analyst says

Nine hundred sales reps are out in the field promoting Orexigen's obesity med Contrave, thanks to the company's marketing partner, Takeda. But for what?

Apollo uses long-term data to defend Lap-Band, as U.S. obesity device options expand

Apollo Endosurgery nabbed an FDA approval for its Orbera Intragastric Balloon in August--which was the third obesity device approved by the agency this year. But Apollo isn't relinquishing its grip on long-standing obesity device Lap-Band, which has faced critiques both on safety and efficacy.

UC Berkeley team says brown fat implants may effectively tackle obesity

A team of scientists at UC Berkeley have developed a technique that utilizes the protective effects of brown fat--which may potentially lead to a new approach to manage obesity, diabetes and other metabolic disorders.

Pfizer, OrbiMed back $40M Rhythm round for rare genetic disease R&D

Boston-based Rhythm has gone back to the venture well to draw up a fresh $40 million in backing from some A-list investors to fuel a mid-stage program for rare genetic disorders linked with a lethal level of obesity.

Vitamin B3 pathway may lead to new obesity drugs

Researchers at Beth Israel Deaconess Medical Center say that a newly discovered vitamin B3 pathway could prove fruitful in pursuing new drugs for obesity, diabetes and other metabolic conditions.

UBC team stakes a claim on a newly discovered 'obesity gene'

By silencing a gene which encodes the protein 14-3-3zeta, scientists at the University of British Columbia say they were able to halve the amount of white fat in mice, possibly opening the door to a new approach to fighting obesity.

Israeli med tech studies breath test in clinical trial for obesity-related cirrhosis candidate

The clinical evaluation of cirrhosis can rely upon a whole range of standard medical tests including hepatic venous pressure gradient (HVPG), liver biopsy results, and liver stiffness testing. But Israeli med tech Exalenz Bioscience is working to develop a breath test for its BreathID system that could offer accurate diagnosis and monitoring for a version of the disease, NASH cirrhosis in a Phase II clinical trial with biotech micro-cap Galectin Therapeutics.